Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 11Lung Neoplasms 3Brain Neoplasms 2ALK-positive Advanced NSCLC 2Neuroma, Acoustic 1Neurofibromatosis 2 1Neoplasm Metastasis 1NSCLC 1Meningioma 1Lymphoma, Large-Cell, Anaplastic 1Gastrointestinal Neoplasms 1Ependymoma 1Carcinoma, Pancreatic Ductal 1Carcinoma 1Breast Neoplasms 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × brigatinib × Clear all
NCT04634110 2022-10-24

Brigatinib Before Brain Irradiation Trial (B3i Trial)

University of Colorado, Denver

Phase 2 Terminated
1 enrolled 6 charts
CNSThoracic

Brain Neoplasms, Lung Neoplasms

NCT03868423 2022-02-18

Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers

Ohio State University Comprehensive Cancer Center

Phase 2 Withdrawn
CNS

Brain Neoplasms, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡